18FDG-PeT/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this study was to evaluate fludeoxyglucose-positron emission tomography/CT's (FDG-PET/CT) performance in the follow up of patients with surgically treated oesophageal adenocarcinoma. Methods: The follow-up FDG-PET/CT scans of 162 consecutive patients with surgically treated oesophageal adenocarcinoma were retrospectively reviewed. Histopathological and/or imaging examinations confrmed recurrent disease. The accuracy, sensitivity, specifcity and negative and positive predictive values were calculated. Results: Recurrence occurred in 71 (43%) patients, usually within the frst year following surgery (60%) and in more than one site (76%). The sensitivity, specifcity, positive-predictive value, negative-predictive value and accuracy of FDG-PET/CT for anastomotic recurrence were 77, 76, 16, 98 and 76%; for regional nodal recurrence were 88, 85, 43, 97 and 86%; and for distant metastatic recurrence were: 97, 96, 91, 99 and 96%. In 5 of the 42 patients (12%) with distant metastases, the metastatic sites were outside the area covered by a conventional follow-up chest-abdomen CT and in 4 patients (9%) metastases were barely perceptible on the CT component of the FDG-PET/CT and consequently were unlikely to be detected without the aid of the FDG uptake. Conclusion: FDG PET/CT is accurate in detecting oesophageal adenocarcinoma recurrence, especially within the frst post-operative year when most recurrences occur, and is useful in identifying patients with a solitary metastasis. Advances in knowledge: FDG-PET/CT should be considered as a valuable tool in the routine follow up of surgically treated oesophageal cancer patients within the frst 2 years after surgery.

LanguageEnglish (US)
Article number20170341
JournalBritish Journal of Radiology
Volume91
Issue number1082
DOIs
StatePublished - Jan 1 2018

Fingerprint

Fluorodeoxyglucose F18
Adenocarcinoma
Positron-Emission Tomography
Recurrence
Neoplasm Metastasis
Esophageal Neoplasms
Abdomen
Thorax

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{f6bb466079e44cc8bd7ab19fc381cf38,
title = "18FDG-PeT/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma",
abstract = "Objective: The purpose of this study was to evaluate fludeoxyglucose-positron emission tomography/CT's (FDG-PET/CT) performance in the follow up of patients with surgically treated oesophageal adenocarcinoma. Methods: The follow-up FDG-PET/CT scans of 162 consecutive patients with surgically treated oesophageal adenocarcinoma were retrospectively reviewed. Histopathological and/or imaging examinations confrmed recurrent disease. The accuracy, sensitivity, specifcity and negative and positive predictive values were calculated. Results: Recurrence occurred in 71 (43{\%}) patients, usually within the frst year following surgery (60{\%}) and in more than one site (76{\%}). The sensitivity, specifcity, positive-predictive value, negative-predictive value and accuracy of FDG-PET/CT for anastomotic recurrence were 77, 76, 16, 98 and 76{\%}; for regional nodal recurrence were 88, 85, 43, 97 and 86{\%}; and for distant metastatic recurrence were: 97, 96, 91, 99 and 96{\%}. In 5 of the 42 patients (12{\%}) with distant metastases, the metastatic sites were outside the area covered by a conventional follow-up chest-abdomen CT and in 4 patients (9{\%}) metastases were barely perceptible on the CT component of the FDG-PET/CT and consequently were unlikely to be detected without the aid of the FDG uptake. Conclusion: FDG PET/CT is accurate in detecting oesophageal adenocarcinoma recurrence, especially within the frst post-operative year when most recurrences occur, and is useful in identifying patients with a solitary metastasis. Advances in knowledge: FDG-PET/CT should be considered as a valuable tool in the routine follow up of surgically treated oesophageal cancer patients within the frst 2 years after surgery.",
author = "{Betancourt Cuellar}, {Sonia Liliana} and Palacio, {Diana P.} and Wu, {Carol C.} and Brett Carter and Correa, {Arlene M} and Hofstetter, {Wayne L} and Marom, {Edith M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1259/bjr.20170341",
language = "English (US)",
volume = "91",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1082",

}

TY - JOUR

T1 - 18FDG-PeT/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma

AU - Betancourt Cuellar, Sonia Liliana

AU - Palacio, Diana P.

AU - Wu, Carol C.

AU - Carter, Brett

AU - Correa, Arlene M

AU - Hofstetter, Wayne L

AU - Marom, Edith M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: The purpose of this study was to evaluate fludeoxyglucose-positron emission tomography/CT's (FDG-PET/CT) performance in the follow up of patients with surgically treated oesophageal adenocarcinoma. Methods: The follow-up FDG-PET/CT scans of 162 consecutive patients with surgically treated oesophageal adenocarcinoma were retrospectively reviewed. Histopathological and/or imaging examinations confrmed recurrent disease. The accuracy, sensitivity, specifcity and negative and positive predictive values were calculated. Results: Recurrence occurred in 71 (43%) patients, usually within the frst year following surgery (60%) and in more than one site (76%). The sensitivity, specifcity, positive-predictive value, negative-predictive value and accuracy of FDG-PET/CT for anastomotic recurrence were 77, 76, 16, 98 and 76%; for regional nodal recurrence were 88, 85, 43, 97 and 86%; and for distant metastatic recurrence were: 97, 96, 91, 99 and 96%. In 5 of the 42 patients (12%) with distant metastases, the metastatic sites were outside the area covered by a conventional follow-up chest-abdomen CT and in 4 patients (9%) metastases were barely perceptible on the CT component of the FDG-PET/CT and consequently were unlikely to be detected without the aid of the FDG uptake. Conclusion: FDG PET/CT is accurate in detecting oesophageal adenocarcinoma recurrence, especially within the frst post-operative year when most recurrences occur, and is useful in identifying patients with a solitary metastasis. Advances in knowledge: FDG-PET/CT should be considered as a valuable tool in the routine follow up of surgically treated oesophageal cancer patients within the frst 2 years after surgery.

AB - Objective: The purpose of this study was to evaluate fludeoxyglucose-positron emission tomography/CT's (FDG-PET/CT) performance in the follow up of patients with surgically treated oesophageal adenocarcinoma. Methods: The follow-up FDG-PET/CT scans of 162 consecutive patients with surgically treated oesophageal adenocarcinoma were retrospectively reviewed. Histopathological and/or imaging examinations confrmed recurrent disease. The accuracy, sensitivity, specifcity and negative and positive predictive values were calculated. Results: Recurrence occurred in 71 (43%) patients, usually within the frst year following surgery (60%) and in more than one site (76%). The sensitivity, specifcity, positive-predictive value, negative-predictive value and accuracy of FDG-PET/CT for anastomotic recurrence were 77, 76, 16, 98 and 76%; for regional nodal recurrence were 88, 85, 43, 97 and 86%; and for distant metastatic recurrence were: 97, 96, 91, 99 and 96%. In 5 of the 42 patients (12%) with distant metastases, the metastatic sites were outside the area covered by a conventional follow-up chest-abdomen CT and in 4 patients (9%) metastases were barely perceptible on the CT component of the FDG-PET/CT and consequently were unlikely to be detected without the aid of the FDG uptake. Conclusion: FDG PET/CT is accurate in detecting oesophageal adenocarcinoma recurrence, especially within the frst post-operative year when most recurrences occur, and is useful in identifying patients with a solitary metastasis. Advances in knowledge: FDG-PET/CT should be considered as a valuable tool in the routine follow up of surgically treated oesophageal cancer patients within the frst 2 years after surgery.

UR - http://www.scopus.com/inward/record.url?scp=85041320608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041320608&partnerID=8YFLogxK

U2 - 10.1259/bjr.20170341

DO - 10.1259/bjr.20170341

M3 - Article

VL - 91

JO - British Journal of Radiology

T2 - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1082

M1 - 20170341

ER -